Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT oculus: Efgartigimod PH20 SC in Adult Ocular Myasthenia Gravis
jRCT2011240058Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Mar 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of efgartigimod alfa + hyaluronidase-qvfc in myasthenia gravis (MG) (3 arms), sponsored by argenx. Primary endpoint: Myasthenia Gravis Impairment Index (MGII) PRO ocular score change from baseline to Day 29 in Part A. Started Mar 2025; status: active, not recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2011240058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240058.